ZURA – zura bio limited - class a ordinary shares (US:NASDAQ)

News

Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com